Úspěšný odběr periferních krvetvorných buněk u pacientky s chronickou myeloidní leukemií léčenou nilotinibem. Kazuistika
Authors:
S. Vokurka 1; D. Lysák 1; M. Karas 1; V. Koza 1; P. Dvořák 2; M. Hrabětová 1; P. Jindra 1; V. Vozobulová 1
Authors‘ workplace:
Hematologicko-Onkologické oddělení a 2Oddělení lékařské genetiky, Fakultní nemocnice Plzeň
1
Published in:
Transfuze Hematol. dnes,16, 2010, No. 2, p. 101-103.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Here we report a case of successful mobilization and harvest of peripheral hematopoietic stem cells in imatinib pretreated and nilotinib treated 52-years old woman, who was diagnosed with chronic myeloid leukemia, Sokal and Hasford intermediate risk group, in 2002. She failed interferon-alfa and imatinib treatment and achieved first complete molecular remission after 16 months of nilotinib treatment. The patient was mobilized with filgrastim at the dose of 10 μg/kg/day. On the day +4, single leukapheresis was performed and autologous graft containing 2,9 x 106/kg CD34+ cell was harvested. The apheresis product was cryopreserved and analyzed: the RT-PCR analysis revealed BCR-ABL positivity (BCR-ABL/ABL ratio 0,0017 in RQ-PCR), the FISH analysis was negative. To our knowledge, this is the first report of successful PBSC harvest in a patient significantly pretreated with imatinib and nilotinib.
Key words:
nilotinib, apheresis, chronic myeloid leukemia
Sources
1. Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
2. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 2006; 37: 1069-1085.
3. Niederwieser D. HSCT for chronic myeloid leukaemia in adults. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T. The EBMT Handbook 5th Edition – Haematopoietic stem cell transplantation. Forum Service Editor 2008, p. 289-396.
4. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H. Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439-449.
5. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant. 2009; 43: 275-291.
6. Kreuzer KA, Kluhs C, Baskaynak G, Movassaghi K, Dorken B, le Coutre P. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004; 124: 195-199.
7. Bhatia R, Xu H, Snyder D, et al. Feasibility and efficacy of mobilization of BCR/ABL- PBSC in CML patients receiving imatinib. Blood 2004; 104: 2858.
8. Weisberg E, Manley PW, Breitenstein W. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
9. JŅrgensen H, Allan E, Jordanides N, Mountford J, Holyoake T. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016-4019.
10. Kantarjian H, Giles F, Bhalla K, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol 2009; 27(15S): 7029.
11. Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
12. Rea D, Raffoux E, Cayuela JM, Maarek O, Dombret H. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia. Leukemia 2009; 23: 1158-1159.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2010 Issue 2
Most read in this issue
- Treatment of relapsed and refractory Hodgkin lymphoma
- Global assessment of haemostagic function - part I. Thrombin generation test
- The detection of TP53 mutations in chronic lymphocytic leukemia
- Short morphometric notes to the heterogeneity of lymphocytes in the peripheral blood („a minireview“ with own original results)